Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript
Immunic, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.51.
Source: insidermonkey.com
Page 2 - Daniel Vitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Daniel Vitt Today - Breaking & Trending Today
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on...
Source: marketscreener.com
Biotech Stock News Bite - Immunic, Inc. (Nasdaq: IMUX) Year End 2023 Financial Results and Provides Corporate Update
Biotech Stock News Bite - Immunic, Inc. (Nasdaq: IMUX) Year End 2023 Financial Results and Provides Corporate Update
Source: investorideas.com
Immunic to Participate in Investor and Scientific Conferences in February
NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...
Source: marketscreener.com
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Source: prnewswire.com